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A B S T R A C T
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a
familial progressive degenerative disorder and is caused by mutations in NOTCH3 gene. Previous study reported
that mutant NOTCH3 is more prone to form aggregates than wild-type NOTCH3 and the mutant aggregates are
resistant to degradation. We hypothesized that aggregation or accumulation of NOTCH3 could be due to im-
paired lysosomal-autophagy machinery in VSMC.
Here, we investigated the possible cause of accumulation/aggregation of NOTCH3 in CADASIL using cerebral
VSMCs derived from control and CADASIL patients carrying NOTCH3R133C mutation. Thioﬂavin-S-staining
conﬁrmed the increased accumulation of aggregated NOTCH3 in VSMCR133C compared to VSMCWT. Increased
levels of the lysosomal marker, Lamp2, were detected in VSMCR133C, which also showed co-localization with
NOTCH3 using double-immunohistochemistry. Increased level of LC3-II/LC3-I ratio was observed in VSMCR133C
suggesting an accumulation of autophagosomes. This was coupled with the decreased co-localization of NOTCH3
with LC3, and Lamp2 and, further, increase of p62/SQSTM1 levels in VSMCR133C compared to the VSMCWT. In
addition, Western blot analysis indicated phosphorylation of p-ERK, p-S6RP, and p-P70 S6K. Altogether, these
results suggested a dysfunction in the autophagy-lysosomal pathway in VSMCR133C.
The present study provides an interesting avenue of the research investigating the molecular mechanism of
CADASIL.
1. Introduction
Cerebral autosomal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy (CADASIL), an inherited small vessel disease,
is characterized by neurological signs such as strokes, migraine with
aura and cognitive impairment (Dichgans et al., 1998). Pathological
characteristics in CADASIL brain are deposits of granular osmiophilic
material (GOM) in close vicinity to the basement membrane of small
diameter arterioles, and degeneration of vascular smooth muscle cells
(VSMCs) (Ruchoux et al., 1994; Ruchoux and Maurage, 1997). VSMC
degeneration occurs with subsequent massive ﬁbrotic thickening of the
vessel walls (Miao et al., 2004) and narrowing of the lumina of small
penetrating arterioles in cerebral white matter.
The onset of CADASIL is from 25 to 60 years-of-age with recurrent
strokes leading to progressive cognitive decline and ﬁnally to dementia.
The correct diagnosis of CADASIL patients is diﬃcult since most pa-
tients initially experience migraine with aura that is often miss-diag-
nosed as migraine. The disease is caused by mutations in the NOTCH3
gene (Joutel et al., 1996); therefore the gold standard for diagnosis of
CADASIL is genetic testing. Furthermore, white matter changes ob-
served via magnetic resonance imaging (MRI) are a characteristic fea-
ture of CADASIL that have been utilized as an indication of the disease.
The pathological characteristic deposits; GOM, have also been observed
extracellularly in skin, retina, muscle (Ruchoux et al., 1994), which
have also functioned as additional standard for diagnosis of CADASIL
by electron microscopy. Up to now there are no clinical tests that can be
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taken readily and inexpensively in helping for diagnosis of CADASIL.
NOTCH3 is a member of the NOTCH receptor family, which is ex-
pressed in arterial VSMCs and pericytes (Joutel et al., 2000, 1996;
Prakash et al., 2002). Members of this type I transmembrane protein
family (Andersson et al., 2011; Artavanis-Tsakonas et al., 1999) share
structural characteristics that include an extracellular domain (ECD)
with a large number of tandemly organized epidermal growth factor-
like (EGF) repeats, a transmembrane spanning sequence, and an in-
tracellular domain (ICD) (Borggrefe and Oswald, 2009; Wang et al.,
2002). There are at least 230 CADASIL causing mutations, which are
located within the EGF repeats, and almost all lead to the change in
number of cysteine residues from even to odd (Tikka et al., 2014).
These mutations may have various functional consequences on the
NOTCH3 receptor, including abnormal folding or dimerization, im-
pairment of interaction with its ligands, and aberrant interaction with
other proteins (Joutel et al., 1997). The unpaired cysteine residues can
prompt mutated NOTCH3ECD to fold abnormally (Opherk et al., 2009)
or bind to another cysteine-containing protein (Arboleda-Velasquez
et al., 2011). Indeed, accumulation of NOTCH3ECD has been found on
the surface of VSMCs and in the deposition of GOM (Ishiko et al., 2006).
Further, proteomic analysis of human brain vessels carrying the CA-
DASIL mutation, identiﬁed clusterin and collagen 18 α1/endostatin as
GOM components linking to hypomorphic NOTCH3 function
(Arboleda-Velasquez et al., 2011; Joutel et al., 2000). Also, in diﬀerent
experimental system and pathological investigations on patient derived
tissues, mutated NOTCH3 receptors appears to misfold and form in-
tracellular aggregates (Karlstrom et al., 2002; Takahashi et al., 2010). It
is not clear whether formation of intracellular NOTCH3 aggregates is a
result of impaired NOTCH3 intracellular traﬃcking and maturation or
defects in lysosomal clearance process. Therefore, it is likely that CA-
DASIL represents another example of a misfolded protein disorder.
The mutant N-terminal sequences of NOTCH3 has inﬂuenced pro-
cessing and function of its expression in the cytoplasm (Karlstrom et al.,
2002). Previous studies showed that the degradation of ICDs of
NOTCH1 and NOTCH4 is controlled by the ubiquitin–proteasome
system (UPS), though more recent work demonstrated that NOTCH1ICD
is also controlled by lysosomal degradation (Jia et al., 2009).
Autophagy impacts VSMCs survival and function. There are three
diﬀerent ways through which endogenous proteins and particles can be
delivered to the lysosome for degradation: chaperon-mediated autop-
hagy (CMA), microautophagy and macroautophagy (Ciechanover,
2005). Macroautophagy (hereafter called autophagy) is capable of de-
grading aggregations, and is therefore a rather interesting candidate for
the degradation of aggregated NOTCH3 (Ciechanover and Kwon,
2015). Alterations in autophagy has been documented in VSMC in re-
sponse to various stimuli, resulting in modulation of VSMC functions,
including proliferation, migration, matrix secretion, contraction/re-
laxation, and diﬀerentiation (Tai et al., 2016). Each of these changes in
VSMC functions plays a critical role in the development of vascular
diseases. Importantly, emerging evidence demonstrates that autophagy
deﬁciency in VSMCs would contribute to atherosclerosis and restenosis,
shedding novel light on therapeutic target of the vascular disorders (Tai
et al., 2016). Deﬁcits in the autophagy-lysosomal pathway result in
protein aggregation, generation of toxic protein species, and accumu-
lation of dysfunctional organelles, which are hallmarks of many neu-
rodegenerative disorders (Ciechanover and Kwon, 2015; Martini-Stoica
et al., 2016; Zhang et al., 2009).
While there have been studies on the topic of NOTCH3ECD ag-
gregations, few studies investigated whether accumulation/aggregation
and degradation of intracellular mutated NOTCH3 in CADASIL. In this
report, we investigated the autophagic-lysosomal pathway in CADASIL
by studying lysosome numbers, and localization of NOTCH3 in lyso-
somes as well as autophagosomes. In addition, we have also studied a
few proteins involved in the signal pathway of ERK/MAPK related to
autophagy function. We used a cell line of cerebral VSMCs origin from
CADASIL patients carrying NOTCH3R133C mutation and healthy control
and discuss the implications of these ﬁndings for the pathogenesis of
CADASIL.
2. Material and methods
2.1. Cell lines
Patient-derived cerebral arterial VSMC (VSMCR133C) as well as
control VSMC (VSMCWT) cell lines were established from post mortem
subarachnoidal branches of cerebral arteries (human cerebral arterial
VSMC) (Gimbrone et al., 1974; Ihalainen et al., 2007; Tikka et al.,
2012). CADASIL patients and control subjects were genetically veriﬁed
by the presence or absence of mutations as previously described
(Panahi et al., 2018).
The ethical permission of human VSMCs carrying mutation and
controls has been approved from the Ethical Board of the Hospital
District of Varsinais-Suomi and Turku University Hospital, the National
Authority for Medicolegal Aﬀairs in Finland, and by the regional Ethical
review board of Stockholm, Sweden (Dnr: 2016/1275-31/4).
2.2. Cell culture
The VSMCWT and VSMCR133C were grown in DMEM/Nutrient
Mixture F-12 with GlutaMAX (Thermo Fisher Scientiﬁc, U.S.A.), sup-
plemented with 10% heat inactivated fetal bovine serum (HI-FBS,
Gibco, Invitrogen), and Penicillin-Streptomycin (100 U/mL/100 μg/
mL) at 37 °C. Cells were cultured continuously under standard cell
culture conditions and passaged every 2–3 days.
2.3. Treatments
VSMCWT and VSMCR133C were treated with chloroquine (CQ)
(25 μM; Sigma Aldrich) diluted in complete medium at variant time
points. CQ inhibits lysosome protein degradation by increasing lyso-
some pH, which inhibits its proteolytic enzymes and causes the accu-
mulation of autophagic vacuoles (Geng et al., 2010; Wibo and Poole,
1974). CQ concentrations were based on values presented by a previous
report (Jia et al., 2009).
2.4. Real time quantitative RT-PCR
VSMCWT and VSMCR133C were grown overnight in a 6-well plate
chamber with conﬂuence of 100.000 cells. The following day, the cells
were lysed with RIPA buﬀer (ThermoFisher Scientiﬁc, U.S.A.) and the
quality of RNA was determined with RIN (RNA Integrity Number) of 10.
cDNA was prepared using Taqman gene expression master mix (Applied
Biosystem) and SuperScript VILO cDNA Synthesis kit (ThermoFisher
Scientiﬁc, U.S.A.) according to the manufacturer's protocol.
Quantitative (q) RT-PCR was performed using costume format TaqMan
fast plate (Applied Biosystems). All probes were used in duplicates with
30 ng of cDNA. Quantitative RT-PCR was performed on a 7500 Fast
Real-Time PCR System (Life Technologies, U.S.A.). The expressions of
genes were normalized to internal control HPRT gene and analysis was
used comparing the normalized value of VSMCWT cell line to the nor-
malized values of VSMCR133C cell line. All the quantitative data were
from three independent biological replicates for each experiment and
the control value was normalized to 1.
2.5. Immunohistochemical analyses
2.5.1. NOTCH3 single staining and confocal analysis
The cultured VSMCWT and VSMCR133C were washed twice with
phosphate buﬀered saline (PBS) and ﬁxed with 4% paraformaldehyde
(Sigma Aldrich) for 10min at room temperature (RT). After ﬁxation the
samples were washed with PBS, and treated with 0.2% Triton X-100 in
PBS for 20min at RT. The cells were then washed again with PBS and
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incubated with 1% bovine serum albumin (BSA; Sigma Aldrich) for
30min. Then the cells were washed again with PBS and incubated with
Protein block serum (DAKO) for 15min at RT to block unspeciﬁc
binding sites. Following incubation with primary human anti-NOTCH3
that target the C-terminus of NOTCH3 (ICD) (Santa Cruz Biotechnology,
[M20], dilution 1:250) overnight (ON) at 4 °C, the cells were washed
with PBS and blocked with 3% normal goat serum in PBS for 15min at
RT. Later the cells were incubated with the secondary antibody Alexa
Fluor 488-conjugated anti-goat IgG (Invitrogen; dilution 1:800) for 1 h
at RT in 0.2% Triton X-100/3% normal goat serum. A cell sample in-
cubated with only secondary antibodies was used as a negative control.
After the staining, the cells were washed, ﬁxed and mounted using
VECTASHIELD mounting medium with DAPI (Vector Laboratories Inc).
All immunoﬂuorescent imaging was performed of a Zeiss META LM510
system. We have only used NOTCH3 antibodies that recognized the C
terminus of NOTCH3 (ICD) in this study.
2.6. NOTCH3 aggregations
Immunocytochemistry and confocal analyses was performed to in-
vestigate intracellular aggregation of NOTCH3 in VSMCR133C and
VSMCWT. Brieﬂy, the cultured VSMCs were washed twice with PBS and
ﬁxed with 10% formalin solution (Sigma-Aldrich) for 5min at RT.
Following washing with PBS, the cells were stained with thioﬂavin S
(Thio-S) (1 mg/mL or 3 μM), diluted 1:50 in PBS, for 5min at RT. For
co-staining with NOTCH3 antibody, the VSMCR133C and VSMCWT were
incubated with 0.3% Triton X-100 diluted in PBS for 20min at RT for
permeabilization. After washing with PBS, the blocking step was car-
ried out by incubating the cells for 30min with 1% bovine serum al-
bumin (BSA, Sigma) diluted in PBS. The cells were then incubated over
night with primary antibodies; NOTCH3 (ICD) (Santa Cruz
Biotechnology, A-6, 1:250 dilutions) at 4 °C. The following day, the
samples were washed 3 times with PBS and incubated for 1 h with the
secondary antibody; Alexa Fluor 546 donkey anti-mouse, (Invitrogen,
1:400 dilution). After washing with PBS, the samples were mounted
with mounting medium containing DAPI (Vector Laboratories Inc). All
immunoﬂuorescent imaging was performed of a Zeiss META LM510
system.
2.7. NOTCH3 and Lamp2
For co-localization of NOTCH3 with lysosomes, the VSMCWT and
VSMCR133C were stained with mouse Lamp2 antibody (abcam, dilution
1:200) to visualize the lysosomes, and co-stained with NOTCH3 (ICD)
antibody (Santa Cruz Biotechnology, M20, dilution 1:250). VSMCs were
exposed to CQ and incubated for diﬀerent incubation times (0, 1, 4, and
24 h). After staining, the VSMCs were washed, ﬁxed and mounted as
described above.
2.8. NOTCH3 and p62/SQSTM1
For co-localization of NOTCH3 with autophagy marker, the
VSMCWT and VSMCR133C were stained with anti-p62/SQSTM1 antibody
(Cell Signalling, rabbit, 1:300 dilutions), and NOTCH3 (ICD) (Santa
Cruz Biotechnology, mouse clone: A-6, 1:250 dilutions). The staining
procedure was done as described above. After staining, the VSMCs were
washed, ﬁxed and mounted as described above.
2.9. NOTCH3 triple-staining with lysosomal and autophagy markers
For co-localization of NOTCH3 with lysosomal and autophagy
markers, before and after treatment, triple immunostaining was also
performed. The VSMCWT and VSMCR133C were treated with CQ for 24 h.
The staining procedure was done as described above. The antibodies
used for triple staining were: anti-LC3 (NB100-2331, Novus
Biotechnology; dilution 1:200), anti-Lamp2 (Lysosome-associated
membrane protein 2) (ab25631, Abcam; dilution 1:200), and anti-
NOTCH3 (Santa Cruz Biotechnology, clone. M20) followed by incuba-
tion with secondary antibodies Alexa Fluor 633-conjugated anti-rabbit
(Invitrogen; dilution 1:500), and Alexa Fluor 546-conjugated, anti-
mouse (Invitrogen; dilution 1:200), and Alexa Fluor 488-conjugated
anti-goat.
Images were acquired using a Zeiss META LM510 system. Analysis
of the images was carried out using the “Analyse Particles” function on
the software ImageJ.
2.10. Quantiﬁcation of triple staining
The number of lysosomes in VSMCWT and VSMCR133C quantiﬁed
prior to and after CQ-treatment. Approximately 20 VSMCs were
counted for each sample. For the autophagosomes, ﬁrst the LC3-posi-
tive dots were counted, and then LC3-positive dots that co-localized
with NOTCH3 and Lamp2, or LC3-Lamp2-NOTCH3 were calculated.
2.11. Western blotting
The untreated and CQ-treated VSMCWT and VSMCR133C (3.0× 105
cells/well) were grown to 70% conﬂuence. Then, the VSMCs were
washed twice with PBS, collected and lysed by lysis buﬀer (0.65%
NP40, 10mM Tris pH 8.0, 1 mM EDTA, 150mM NaCl) containing
protease inhibitors (Mammalian ProteaseArrest; G-Biosciences).
Samples were incubated on ice for 15min, with a ten second vortex
interval every two min. Cell debris was cleared by centrifugation at 13
200 rpm for 10min at 4 °C. The samples were concentrated through
rotary evaporation. Total protein content was measured using the
Pierce BCA Protein Assay Kit (Thermo Scientiﬁc). Total protein extracts
(10–25 μg) were mixed with 2× SDS sample buﬀer (Sigma Aldrich),
boiled for 5min and loaded onto NuPAGE 4–12% or 12% Bis-Tris (Life
Technologies) using NuPAGE MES or MOPS SDS Running Buﬀer (Life
Technologies). Gels were blotted with the wet tank transfer system
(Hoefer) using Amersham Protran 0.45 μm Nitrocellulose membrane
(GE Healthcare Life Sciences) and transfer buﬀer (20mM Tris-HCl pH
8.6, 120mM glycine, 20% methanol). The membranes were blocked
using 5% milk (Semper) in TBS-T (20mM Tris pH 7.5, 150mM NaCl,
0.1% Tween 20). After two TBS-T washing steps the membranes were
incubated over night at room temperature or 4 °C with the primary
antibodies (see Table 1) diluted in 5% milk and 0.2% sodium azide. The
membranes were washed with TBS-T and incubated with speciﬁc sec-
ondary antibodies, anti-rabbit and anti-mouse IgG conjugated with
horseradish peroxidase (HRP; GE Healthcare) for 1 h, at RT. Using
Table 1
List of primary antibodies used for western blot (WB) and immunoﬂuorescence
(IF) techniques.
Antigen Host Dilution Source WB vs. IF
ERK Mouse 1:1000 BD Biosciences WB
pERK R1abbit 1:1000 Cell Signalling Technology WB
mTOR Rabbit 1:1000 Cell Signalling Technology WB
pmTOR Rabbit 1:1000 Cell Signalling Technology WB
S6 RP Mouse 1:1000 Cell Signalling Technology WB
pS6 RP Rabbit 1:1000 Cell Signalling Technology WB
P70 S6K Rabbit 1:1000 Cell Signalling Technology WB
pP70 S6K Rabbit 1:1000 Cell Signalling Technology WB
p62/SQSTM Rabbit 1:1000 Cell Signalling Technology IF/WB
LC3 Rabbit 1:2000 Cell Signalling Technology WB
LC3 Rabbit 1:200 Novus Biotechnology IF
Lamp1 Mouse 1:500 Santa Cruz Biotechnology WB
Lamp2 Mouse 1:200-1:500 Abcam IF/WB
GAPDH Mouse 1:1000 Sigma-Aldrich WB
NOTCH3 Goat 1:250 Santa Cruz Biotechnology IF
NOTCH3 Mouse 1:250 Santa Cruz Biotechnology IF
NOTCH3 Rabbit 1:1000 Cell Signaling Technology WB
Ubiquitin Rabbit 1: 500 Enzo Life Sciences WB
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chemiluminescent HRP substrate (Merck Millipore), the membranes
were visualised. Autoradiography using Amersham Hyperﬁlm ECL (GE
Healthcare) and digital imaging camera (FujiFilm LAS-3000 camera)
was used for detection and the later for semi-quantitative analysis. The
visualization of several WB analyses was also performed using Odyssey
CLx Imaging system (Li-Cor) and ImageStudio software was used to
visualize the blot. The secondary antibodies; anti-mouse Li-Cor IR Dye
800CW and anti-rabbit Li-Cor IR Dye 680CW were used.
2.12. Statistical analysis
Statistical comparison of values obtained for VSMC cell lines was
performed by one-way ANOVA followed by Bonferroni’s post-hoc test.
Student t-test was used for two-group comparisons. p-values< 0.05
were considered signiﬁcant. The results are representative of three in-
dependent biological replicates expressed as mean ± S.E.M. For lyso-
some quantiﬁcation, approximately 20 VSMCs were counted for each
sample using ImageJ (Abramoﬀ et al., 2004). Western blot analysis was
quantiﬁed by ImageJ software.
Fig. 1. Analysis of NOTCH3 accumulation in VSMCWT
and VSMCR133C. (A) Quantitative RT-PCR analysis of
NOTCH3 gene. The expression level of NOTCH3 gene
is 2.6 fold higher in VSMCR133C than in VSMCWT. The
data is from two independent experiments. The ex-
pression of NOTCH3 gene is normalized to the en-
dogenous control gene, HPRT1, and the RQ (Relative
Quantitation) is calculated using VSMCWT as a re-
ference. (B) Western blot analysis demonstrates in-
creased accumulation of NOTCH3 (∼102 kDa) in
VSMCR133C compared to VSMCWT. (C) VSMCWT and
VSMCR133C are visualised by immunostaining using
NOTCH3 antibody (green) followed by confocal mi-
croscopy analysis. Nuclei are stained with DAPI (vi-
sualized by red), scale bar= 5 μm. (D) Confocal mi-
croscopy of Thio-S positivity (green) shows more dense
formation of large intracellular aggregates in
VSMCR133C cells. Quantiﬁcation revealed four times
increased aggregate structures in VSMCR133C com-
pared to VSMCWT (right panel, graph) (paired t-test, **
p < 0.01). Values shown are means± S.E.M. (E)
Double staining shows co-localization of aggregated/
accumulated NOTCH3 (red) in Thio-S positive (green)
aggregates. Thio-S: Thioﬂavin-S. (For interpretation of
the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
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3. Results
3.1. NOTCH3 accumulates in VSMCR133C
To conﬁrm expression of NOTCH3 in our cell line, qRT-PCR was
utilized. We observed a 2.6 fold increased NOTCH3 expression in
VSMCR133C compared to the VSMCWT (Fig. 1A). This data was further
conﬁrmed on protein level by western blot (WB) on lysates from
VSMCWT and VSMCR133C cells (Fig. 1B). Both on mRNA and protein
levels NOTCH3 is expressed more in VSMCR133C compared to VSMCWT.
This is a phenotype we have observed previously (Panahi et al., 2018)
and we suggested that the overexpression of NOTCH3 is due to com-
pensatory mechanism of loss of function due to mutation.
To further investigate the expression and distribution of NOTCH3 in
Fig. 2. Lysosomal vesicles in VSMCWT and
VSMCR133C after chloroquine (CQ) treatment.
VSMCWT and VSMCR133C are treated with CQ
for 1, 4 and 24 h. The lysosomes are visualised
by Lamp2 (red) and analysed by confocal mi-
croscopy. Nuclei are stained with DAPI (blue).
Quantiﬁcation of the lysosomes is performed
manually by analysing 20 VSMCs for each
sample. (A) Representative, confocal images
show the lysosomes in VSMCWT and
VSMCR133C before treatment and after CQ
treatment for 1, 4, and 24 h. (B) Lysosomal
numbers are quantiﬁed at four diﬀerent time
points of CQ-treatment. At basal level, the
number of lysosomes is lower in VSMCWT than
VSMCR133C (* p < 0.05). The VSMCR133C has
a higher number of lysosomes compared to
VSMCWT after 24 h (paired t-test, *** p <
0.001). Values are shown as mean± S.E.M.
Scale bar = 5 μm. (C) A representative WB
analyses for detecting Lamp1 is shown (upper
panel). Prior and after 1 h of CQ treatment, the
level of Lamp1 protein is increased in
VSMCR133C. The Lamp1 expression is sig-
niﬁcantly increased after 24 h CQ-treatment (*
p < 0.05) (lower panel, graph). Experiments
are conducted in triplicate. Anti-GAPDH was
used as loading control. (For interpretation of
the references to colour in this ﬁgure legend,
the reader is referred to the web version of this
article.)
Fig. 3. Accumulation of NOTCH3 in lysosomes
of VSMCs. Representative confocal microscopy
images of (A) VSMCWT and VSMCR133C un-
treated and treated with CQ (B) are shown. The
cells are stained with Lamp2 (red), NOTCH3
staining (green), and DAPI (cell nucleus; blue).
An increased co-localization of NOTCH3 in
lysosomes is observed in VSMCR133C after 24 h
CQ treatment (lower panel) compared to un-
treated VSMCR133C. Scale bars= 10 μm.
Experiments are conducted in triplicate. (C) Z-
Stack analysis by confocal microscopy con-
ﬁrmed the localization of NOTCH3 in lyso-
somes (lower panels). Scale bar= 10–20 μm.
CQ: chloroquine. (For interpretation of the re-
ferences to colour in this ﬁgure legend, the
reader is referred to the web version of this
article.)
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VSMCs, we performed confocal microscopy analysis. A dispersed dot-
like staining of NOTCH3 in the cytoplasm of VSMCWT was seen (Fig. 1C,
left), while the staining pattern of NOTCH3 in VSMCR133C displayed
large intense dots/aggregated forms in the cytoplasm (Fig. 1C, right and
middle).
In order to assess intracellular protein aggregation, we performed
Thio-S staining. Confocal microscopy observation of Thio-S positivity
showed more dense formation of large intracellular aggregates in the
cytoplasm of VSMCR133C cells (Fig. 1D), suggesting that in these cells
there are protein aggregations. We also observed a perinuclear accu-
mulation of Thio-S-positive aggregated forms in VSMCR133C cells (data
not shown). Quantiﬁcation revealed four times increased aggregate
structures in VSMCR133C compared to VSMCWT (Fig. 1D and graph). To
examine whether cellular co-localization of aggregated NOTCH3 in
VSMCs, we performed a co-staining using Thio-S and NOTCH3. The
Thio-S-positive aggregates did not completely co-localize with NOTCH3
in VSMCWT cells, a phenotype that was much more pronounced in
VSMCR133C cells suggesting that NOTCH3 mutation causes an in-
tracellular aggregation (Fig. 1E).
3.2. Lysosomes vesicles and dilation after chloroquine (CQ) treatment in
VSMCWT and VSMCR133C
We investigated the level of lysosome-associated membrane protein-
2 (Lamp2) by immunostaining prior to and after CQ, which has been
attributed to an inhibitory eﬀect (Mauthe et al., 2018) on lysosomal
activity by decreasing autophagosome-lysosome fusion. The quantiﬁ-
cation of lysosomes was performed on confocal microscopy images.
Prior to CQ-treatment (0 h), we observed that Lamp2-labelled vesicles
in VSMCR133C were larger than in VSMCWT. After 1 h of exposure to 25
μM CQ, both cell lines showed equal Lamp2-labelled vesicles in their
cytoplasm. After 24 h, lysosomes became greatly dilated in both cell
lines, which were more evident in VSMCR133C (Fig. 2A). Quantiﬁcation
of Lamp2 staining showed signiﬁcantly increased prevalence in
VSMCR133C after CQ treatment compared to VSMCWT (Fig. 2B). Of note,
WB analysis veriﬁed increased level of NOTCH3 in VSMCR133C in
comparison to VSMCWT prior to and after 24 h CQ-treatment (Fig. S1).
We analysed the protein levels of the Lamp1, another major lyso-
somal glycoprotein, by WB. After 1 h of CQ treatment, the level of
Lamp1 protein was signiﬁcantly increased in VSMCR133C compared to
VSMCWT (Fig. 2C). The Lamp1 expression was also increased after 24 h
CQ-treatment (Fig. 2C). The quantiﬁcation of WB analysis of Lamp1
revealed higher Lamp1 protein levels in VSMCR133C after 24 h CQ-
treatment (Fig. 2C, lower panel, graph).
We also examined the levels of ubiquitinated proteins in these cells.
We observed a moderate decrease in global ubiquitination pattern of in
VSMCR133C by WB using mono- and poly-ubiquitin antibody (clone
FK2) (Fig. S2), suggesting that NOTCH3-mutation in VSMCR133C de-
creases the propensity to form cytoplasmic aggregates.
3.3. Co-localization of NOTCH3 with lysosomes
Previously, a study reported lysosomal-dependent degradation of
NOTCH3 (Jia et al., 2009). To examine the possibility that degradation
of aggregated NOTCH3 is related to lysosomal function in VSMCR133C,
we performed immunostaining using anti-NOTCH3 and anti-Lamp2
antibodies followed by confocal microscopy.
Our results showed NOTCH3 co-localization with lysosomes prior to
(Fig. 3A), and after 24 h CQ-treatment in both cell lines (Fig. 3B). The
co-localization of NOTCH3 with lysosomes was more evident in
VSMCR133C (Fig. 3B, C), which might be a result of autophagy dysre-
gulation or a deﬁciency of autophagosomes-lysosomes fusion process
(Terman et al., 2007).
3.4. Higher amount of autophagosomes in VSMCR133C after CQ-treatment
To examine the involvement of the autophagy pathway, we per-
formed WB to detect the protein level of endogenous LC3, a well-es-
tablished autophagosome marker (Klionsky et al., 2012). VSMCWT and
VSMCR133C were treated for 24 h with CQ. Endogenous LC3 is detected
as two bands following SDS-PAGE and immunoblotting: the LC3-I re-
presents the cytosolic form, while LC3-II is present on the membranes of
autophagy vesicles.
Fig. 4A shows a representative WB analysis detecting two LC3
bands, LC3-I and LC3-II (Fig. 4A, upper (low exposed) and middle panel
(high exposed). Prior to CQ-treatment, the amount of LC3-II was barely
observed in cell lines (Fig. 4A). Hence, treatment with CQ for 24 h in-
duced an increase in the level of LC3-II in the VSMCWT and VSMCR133C.
However, the increased level of LC3-II was more obvious in VSMCR133C
than in the VSMCWT (Fig. 4A), indicating a higher number of autop-
hagosomes in CADASIL. Since cytosolic LC3 ratio has been suggested
for a quantitative index of autophagy, the ratio of LC3-II/LC3-I was
examined and quantiﬁed. In the presence of CQ, the LC3-II/LC3-I ratio
was greater in the VSMCR133C compared to the VSMCWT (Fig. 4B),
suggesting that R133C mutation in VSMC cause a dysregulation in
autophagy pathway.
Fig. 4. Expression levels of LC3-I and LC3-II in VSMCWT and VSMCR133C.
Western blot analysis of VSMCWT and VSMCR133C in the absence or presence of
CQ for 24 h. (A) A representative WB analyses for detecting LC3 bands, LC3-I
and LC3-II (upper panel; shorter exposure time). Prior to CQ-treatment, the
amount of LC3-II is barely observed in cell lines (upper panel; shorter exposure
time). While the blot exposed to a longer time revealed LC3-I and LC3-II bands
(middle panel: blot exposed to longer time). VSMCWT and VSMCR133C treated with
CQ for 24 h, show increased levels of LC3-II in both cell lines, which is higher in
VSMCR133C. GAPDH; control for protein loading. (B) Quantitative analysis of
LC3II/LC3I ratio from three independent WB analyses is shown. A signiﬁcant
diﬀerence between LC3-II/LC3-I levels before and after CQ-treatment (paired t-
test, *** p < 0.001) is observed in VSMCR133C. Higher level of LC3-II/LC3-I
ratio is also observed in VSMCR133C compared to VSMCWT before and after
treatment with CQ (* p < 0.05, respectively). Values shown are
means± S.E.M. CQ: chloroquine.
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3.5. Low amount of NOTCH3 in autophagosome vesicles in VSMCR133C
Next, we examined if the autophagy-lysosomal pathway is involved
in the degradation of accumulated NOTCH3 in CADASIL. LC3 is the
only known mammalian protein identiﬁed that stably associates with
the autophagosome membranes. In order to investigate the fusion of
autophagosomes with and to examine whether aggregated/accumu-
lated NOTCH3 is co-localizing with the lysosomal marker, we per-
formed immunostaining with anti-LC3, -Lamp2, and -NOTCH3 anti-
bodies in the absence or presence of CQ, and analysed by confocal
microscopy.
Prior to CQ-treatment, the prevalence of NOTCH3 in LC3-positive
puncta in VSMCWT was relatively less compared to VSMCR133C (Fig. 5A,
B). After CQ-treatment, in agreement with the WB results, a marked
increase of LC3-positive puncta in the cytoplasm of the VSMCR133C was
detected as compared to VSMCWT (Fig. 5B). An increase of LC3-positive
puncta and Lamp2 were observed in both VSMCWT and VSMCR133C after
treatment. Of note, a more intense puncta staining (both LC3 and
Lamp2) was visible in VSMCR133C (Fig. 5C, D). Z-stacks analysis con-
ﬁrmed the co-localization of NOTCH3 in LC3-Lamp2 positive puncta
(Fig. 5E).
Quantiﬁcation of the percentage of LC3-positive puncta co-localized
with NOTCH3 and Lamp2 was performed on VSMCs treated with CQ for
24 h (Fig. 5F). VSMCWT showed relative similar LC3 co-localization
with NOTCH3 compared to VSMCR133C (31.7 ± 4.1% and
33.3 ± 3.8% respectively), however the co-localization of LC3 with
Lamp2 (LC3 + Lamp2, double staining) and combination of NOTCH3
and Lamp2 (LC3 + Lamp2 + NOTCH3, triple staining) was sig-
niﬁcantly decreased in VSMCR133C in comparison to VSMCWT (Fig. 5F).
These data suggest an impairment of the autophagosome-lysosome fu-
sion in VSMCR133C compared to VSMCWT.
Fig. 5. NOTCH3 co-localization with LC3 and Lamp2 in VSMCWT and VSMCR133C. Representative images of confocal microscopy analysis of VSMCWT and VSMCR133C
in untreated (A, B) and after exposure to 24 h exposure to CQ (C; D) are shown. Triple immunoﬂuorescence staining on VSMCs against NOTCH3 (green), LC3
(purple), and Lamp2 (red) in VSMCWT and VSMCR133C is shown (A–D). Nuclei are stained with DAPI (blue). Scale bar= 10–20 μm. (E) Z-stack analysis presenting and
conﬁrming the accumulation and co-localization of NOTCH3 in LC3 and Lamp2. Scale bars= 10–20 μm. (F) Co-localization of LC3 with Lamp2 (double staining) and
combination of NOTCH3 and Lamp2 (triple staining) is signiﬁcantly decreased in VSMCR133C in comparison to VSMCWT (paired t-test, ** p < 0.01, respectively).
VSMCWT showed relative similar LC3 co-localization with NOTCH3 compared to VSMCR133C. Values shown are means ± S.E.M. NS=not signiﬁcant. CQ: chlor-
oquine. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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3.6. Degradation of p62/SQSTM1 by autophagy activity in VSMCR133C
The polyubiquitin-binding protein p62/SQSTM1 is necessary to
target protein aggregates for degradation via autophagy (Bjorkoy et al.,
2006), and/or the ubiquitin-proteasome system (Babu et al., 2005;
Bardag-Gorce et al., 2005; Seibenhener et al., 2004). To investigate
whether the protein clearance was defective in CADASIL cell line, we
analysed the p62/SQSTM1 protein by immunostaining and WB with
and without CQ.
Confocal microscopy analysis revealed higher levels of p62/
SQSTM1 in VSMCR133C as compared to VSMCWT before any treatment
(Fig. 6A, B).
WB analysis showed that the p62/SQSTM1 levels were signiﬁcantly
lower in VSMCWT than in VSMCR133C prior to CQ-treatment (Fig. 6C,
graph). Once treated, higher level of p62/SQSTM1 was observed in both
cell lines. Thus the level of increased p62/SQSTM1 was signiﬁcantly
higher in VSMCR133C than in VSMCWT (Fig. 6C, graph).
3.7. VSMCR133C exhibit phosphorylation of proteins in the ERK/MAPK
signalling pathway
The ERK/MAPK signalling pathway has been linked to the regula-
tion of autophagy (Zhou et al., 2015), and thus could possibly underlie
the observed aberrations. Therefore, the levels of four proteins involved
in the ERK/MAPK signalling pathway; extracellular-signal-regulated
kinase (ERK), S6 ribosomal protein (S6RP), P70 S6 kinase (P70 S6K),
and mammalian target of rapamycin (mTOR), and their phosphorylated
forms were investigated by WB analyses.
Analysis showed equal levels of ERK, S6 RP, and P70 S6K in
VSMCWT and VSMCR133C (Fig. 7). In contrast, the phosphorylated forms
of these proteins were expressed at higher levels in the VSMCR133C
(Fig. 7). mTOR level was signiﬁcantly higher in VSMCR133C whereas
(Fig. 7) its phosphorylated counterpart were not detected in the WB in
either cell line (data not shown).
Fig. 6. Level of p62/SQSTM1 in VSMCWT and VSMCR133C. (A)
Confocal microscopy images representing the expression level of
p62/SQSTM1 in VSMCs. Double immunostaining of p62/SQSTM1
(purple/red) and NOTCH3 (green) is shown. (B) Quantiﬁcation by
ImageJ analysis showed an increased p62/SQSTM1 level at the
basal level (*** p < 0.001). (C) A representative of WB is shown.
VSMCs are cultured in the absence and presence of CQ for 24 h.
The p62/SQSTM1 expression levels are analysed by WB (n=3).
GAPDH has been used as a loading control and the relative in-
tensity of p62/SQSTM1 level is normalized to GAPDH.
Quantiﬁcation of three independent WB analysis demonstrated
higher level of p62/SQSTM1 in VSMCR133C than in VSMCWT prior
to (* p < 0.05) CQ treatment. The level of p62/SQSTM1 is sig-
niﬁcantly higher in VSMCR133C after treatment with CQ compared
to untreated VSMCR133C (*** p < 0.001) (lower panel). ** p <
0.01, Values shown are means± S.E.M. CQ: chloroquine. (For
interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
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4. Discussion
In CADASIL, one of the major pathological hallmarks is loss of
VSMCs and successful autophagy can promote VSMC survival (Gray
et al., 2007). VSMC cells carrying a mutation in the NOTCH3 gene (e.g.
R133C) may be subject to a higher level of intracellular stimuli and/or
insults compared to non-mutated NOTCH3. The VSMC carrying CA-
DASIL mutation is notoriously susceptible to stress; therefore, we
questioned whether the autophagy machinery might be dysregulated as
a consequence of misfolded mutated NOTCH3.
Here, we report increased expression and accumulation of NOTCH3
in VSMCR133C which was partially co-stained with Thio-S positivity in
VSMCR133C indicating NOTCH3 as an aggregated protein in the disease
condition. Furthermore, our results showed reduced localization of
mutated NOTCH3 in the autophagosome-lysosome fusion steps, sug-
gesting that autophagy, is not completely functioning in CADASIL cells.
We found increased immunoreactivity of Lamp2, lysosomal marker,
prior to and after CQ-treatment in VSMCR133C. This data was in line
with a previous study showing increased large lysosomes and lysosomal
inclusions in pericytes in the frontal cortex of transgenic mice expres-
sing Notch3R90C (Gu et al., 2012). Furthermore, using LC3, a well-es-
tablished autophagosome marker (Klionsky et al., 2012), we in-
vestigated whether the autophagy system is dysregulated in VSMCR133C
cells. Accumulation of LC3 may suggest either the autophagy upregu-
lation or a blockage of autophagosome-lysosomal pathway (Rubinsztein
et al., 2009). We observed induced LC3-II/LC3I ratio in VSMCR133C cells
suggesting impaired autophagosome degradation prior to and after CQ
insult; a compound which inhibits lysosome protein degradation (Wibo
and Poole, 1974; Geng et al., 2010).
The autophagic cargo receptor, p62/SQSTM1, is necessary to target
proteins for degradation via autophagy (Pankiv et al., 2007) and ac-
cumulation of p62/SQSTM1 could result from defective autophagy
clearance. Prior to and after CQ-treatment, we observed an increase of
p62/SQSTM1 level in VSMCR133C by confocal microscopy and WB.
Fig. 7. Levels of proteins involved in ERK/MAPK signalling pathway. (A) The VSMCWT and VSMCR133C were lysed and the level of ERK, S6RP, P70 S6K, and
mammalian target of rapamycin (mTOR), and their phosphorylated forms are investigated by WB analyses. The percentage of relative intensity of the bands is
normalized to loading control, GAPDH. Quantiﬁcation of phosphorylated (p)-ERK1/total ERK showed a signiﬁcant increase in VSMCR133C (* p < 0.05). The
phosphorylated forms of p-S6RP and p-p70S6K are expressed at a higher level in the VSMCR133C* (* p < 0.05). The level of mTOR is signiﬁcantly higher in
VSMCR133C compared to VSMCWT (*p < 0.001). Values shown are means± S.E.M. The intensity of all bands is normalized to GAPDH.
Fig. 8. Hypothetical connection of ERK/MAPK signalling pathway and autop-
hagy signalling in CADASIL. Schematic summary of the signalling pathway and
the results is shown. The kinase mTOR is a critical regulator of autophagy in-
duction, with activated mTOR (Akt and ERK/MAPK signalling) suppressing
autophagy, and negative regulation of mTOR (AMPK and p53 signalling) pro-
moting it. However, the activation of the ERK/MAPK pathway can be upregu-
lated via diverse biological processes in cells, e.g. inﬂammation. The phos-
phorylation of ERK1/2 activates p70S6k and S6RP and cause phosphorylation
of these proteins, which in turn might activate/modify autophagy processing.
However, increased p-ERK/MAPK level might inhibit the regulatory eﬀect of
mTOR involved in autophagy. Regardless of that observed increase level of
LC3II/LC3I ratio, P62/SQSTM1 accumulation and lower co-localization of
NOTCH3 in Lamp2/LC3+ cells in VSMCR133C, indicates a deﬁciency of the
fusion steps in autophagic-lysosomal pathway in CADASIL.
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Thus, it is tempting to speculate that the increased accumulation of
aggregated NOTCH3 in p62/SQSTM1-positive structures could be
caused by suppression of autophagy clearance. However, the expression
level of p62/SQSTM1 can also be changed independently of autophagy
(Bardag-Gorce et al., 2005; Kuusisto et al., 2001; Nakaso et al., 2004).
Further, the co-localization of LC3 with Lamp2 (double staining) and
combination of NOTCH3 and Lamp2 (triple staining) was signiﬁcantly
decreased in VSMCR133C in comparison to VSMCWT suggesting an im-
pairment of the autophagosome-lysosome fusion in VSMCR133C. Hence,
we suggest that either autophagy dysregulation or a deﬁciency of au-
tophagosomes-lysosomes fusion take place in CADASIL (Terman et al.,
2007).
It has been proposed that the degeneration of the smooth muscle
layer in arteries/arterioles of CADASIL patients is the result of increased
VSMC death (Gray et al., 2007; Viitanen et al., 2013). Among the
reasons behind VSMC degeneration, dysfunctional autophagy is a pos-
sible factor. The autophagy dysfunction or an insuﬃcient autophagy in
stress conditions has been suggested to be the cause of apoptosis in
CADASIL astrocytes (Hase et al., 2018). Further, the insuﬃcient au-
tophagy has been linked to lower proliferation rate of VSMCs (Panahi
et al., 2018) (here VSMCR133C), and VSMC secreted matrix proteins
suggesting a linkage of autophagy level in the development of vascular
aging (Tai et al., 2016). We have previously demonstrated that the
reduced number of VSMC cells is rather due to impaired VSMC pro-
liferation (Viitanen et al., 2013) showing an important role of TGFβ in
the proliferation process (Panahi et al., 2018). Further, the mutant
NOTCH3 was shown to be more prone to form aggregates than
NOTCH3WT (Takahashi et al., 2010), and that the mutant aggregates
were resistant to degradation, ultimately impairing cell proliferation. In
addition, an altered cytoskeleton structure of VSMCR133C could hamper
the autophagy-lysosomal function through its negative aﬀect on actin
organization (Tikka et al., 2012), causing a defect/delay in autopha-
gosome-lysosome fusion, as well as the co-localization of NOTCH3 in
the organelles involved in this process. As we presented here, the ac-
cumulation of intracellular mutated-NOTCH3 could be a consequence
of low eﬃcacy of autophagy pathway involved in aggregated NOTCH3
in CADASIL. However, the mechanisms leading to autophagy dysfunc-
tion as well as those linking defective autophagy in CADASIL require
further investigation.
Another possible manner by which mutated NOTCH3 could aﬀect
autophagy is through ERK/MAPK pathway (Zhou et al., 2015), which is
activated by NOTCH3 through undeﬁned crosstalk (Wang et al., 2002).
This could be a way in which NOTCH3 mutations lead to a dysregu-
lation in autophagy, either through the constant activation of ERK/
MAPK, or the prevention of the crosstalk necessary for activation and
thus it is a possible cause of these aberrations. WBs indicated hyper-
phosphorylation of three proteins involved in ERK/MAPK signalling
pathway: p-ERK, p-P70 S6K and p-S6 RP. ERK hyper-phosphorylation
disrupts gene expression, and S6 RP is thought to regulate translation
and its hyper-phosphorylation will similarly disrupt gene expression.
The ERK/MAPK pathway also includes mTOR (Wang et al., 2009),
which acts via S6K (Magnuson et al., 2012), providing another way by
which the ERK/MAPK pathway may inﬂuence autophagy (Fig. 8).
Quantiﬁcation of mTOR level was higher in VSMCR133C as compared to
its counterpart and ERK1/2/MAPK activation leads to the inhibition of
mTOR, a negative regulator of autophagy (Wang et al., 2009). All these
data may suggest a dysfunction of the autophagy ﬂux, e.g. the impair-
ment of the autophagosome-lysosome fusion, with consequent accu-
mulation of autophagosomes, lysosomes and their cargo. Hence, we did
not detect phosphorylated mTOR in either cell lines as analysed by WB
(data not shown). As the ERK/MAPK pathway contributes to myriad
aspects of cellular physiology, its activation in CADASIL VSMCs may
implicate other processes in CADASIL pathogenesis, such as insulin
resistance and inﬂammation. In addition, the mechanism by which
NOTCH3 inﬂuences cellular signalling in CADASIL may hold broader
implications for the cellular processes behind more common diseases
like diabetes.
For this study, we acknowledge some limitations. The in vitro data
was based on low numbers of cerebral VSMCs from CADASIL and
control cell lines. Despite that, we were able to demonstrate a possible
dysfunction of autophagosome-lysosomal pathway in CADASIL.
However, we should emphasize the diﬃculties and limitations of pre-
paring cerebral VSMCs derived from CADASIL patients. Furthermore,
supplementary experiments of genes involved in autophagy pathway
are needed.
Taken together, in this study we suggest that the clearance of
NOTCH3 by the autophagosome–lysosome pathway is compromised in
VSMCR133C (Fig. 9). How this process occurs, and what role it plays in
the molecular mechanism of CADASIL remains elusive.
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